福森药业(01652.HK)中期纯利跌55.78%至2365.5万元 中期息每股0.3分
格隆汇8月30日丨福森药业(01652.HK)公布,截至2019年6月30日止中期,实现收益人民币1.96亿元(单位下同),同比减少约27.8%;毛利1.06亿元,同比减少约28.2%;纯利2365.5万元,同比减少55.78%;每股盈利3分,拟派中期息每股0.30分。期内,收入减少主要是由于销量减少所致。
在产品类别中,双黄连口服液的销售收益同比减少约29.6%至9990万元,主要是由于2019年上半年的销量较2018年同期减少约37.4%及平均销售价格较2018年同期上升约12.6%抵消所致。双黄连注射液的销售收益同比减少约44.7%至3690万元,主要是由于销量减少约55.6%所致。来自其他产品的收益同比微增约2.6%至4300万元,主要由于公司持续推广所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.